Virtual Library
Start Your Search
Gulrukh Komiljonovna Botiralieva
Author of
-
+
P2.02 - Biology/Pathology (ID 616)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.02-049 - Immunohistochemical Approach in Predicting Primary Lung Cancer Outcome: A Single Center Study (ID 10130)
09:30 - 16:00 | Presenting Author(s): Gulrukh Komiljonovna Botiralieva
- Abstract
Background:
The death rate from lung cancer in Uzbekistan during 1990 to 2000 increased from 2.1 to 3.1 per 100,000 and in 2016, it reached 3.8 per 100,000 with steady rising. The most prevalent type of lung neoplasm in Uzbekistan is squamous cell carcinoma, whereas in other countries, adenocarcinoma of the lung is considered to be more frequently diagnosed than squamous cell carcinoma. Important key factors in cancer evaluation are diagnosis and prognosis. The aim of this study is directed to determine biological characterization of lung cancer by means of immunohistochemistry, which would be a crucial step towards to therapy.
Method:
Study consisted 564 patients (mean age 58; range, 34-82 years) with primary lung cancer registered at National Cancer Register in the period from 2000 to 2010. All patients were clinically diagnosed, resected, reviewed by a pathologist and followed for at least 72 months. Two different types of oncoproteins were chosen for this analysis: p53, a tumor suppressor gene; and VEGF, vascular endothelial growth factor for detecting the prognostic value of VEGF and its possible association with p53-gene mutation. Overall cancer-specific survival and cancer-free survival or the risk of recurrence was defined from the date ofoperation to the date of recurrence or last follow-up.
Result:
Among the 564 patients, immunoreactivity for VEGF was negative, weakly, moderately and strongly positive in 96 (17%), 141 (25%), 225 (40%) and 102 (18%) cases, respectively. Abnormalities in p53 expression were found in 220 (39%) of 564 carcinomas. A strong, statistically significant association was found between the presence of a p53 gene mutation and expression of VEGF (P<0.001). Tumors with high p53 expression showed significantly higher VEGF, also high expression of p53 correlated with mediastinal and lymph node metastasis. Survival and post-operative relapse time were shorter in patients with high p53 expression. Median follow-up was 34 months (1-72 months). The median time to recurrence was 9 months; the recurrence rate was 310 of 564 (55%). With 5-year follow-up on all patients, actual 5-year survival was 58%.
Conclusion:
P53 overexpression was an indicator of poor prognosis; in addition, it is generally believed that tumors with p53 alterations are more resistant to cancer chemotherapeutic agents than those without p53 mutation. Our study showed that among 40% p53 positive cases have patients with 18% VEGF overexpression, which is the further assay for future studies, the next step will be to examine the capability of target therapy in this group of patients.
